A New 'Omics Emerges | GenomeWeb

A New 'Omics Emerges


There are several reasons why some patients may or may not respond to a drug, or may exhibit a certain side effect that other patients do not. Some of those reasons are genetic, as pharmacogenomics researchers have shown — certain alleles can predict response to a drug or the likelihood of an adverse reaction. But pharmacogenomics has been unable to explain all the variability in drug response, so metabolomics researchers have stepped in to see whether their discipline can help explain why some patients respond to drugs the way they do.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.